When Will Rexulti Go Generic?
The exact date for Rexulti (brexpiprazole) to become available as a generic medication depends on the resolution of ongoing patent litigation. While some patents have expired or are nearing expiration, others are subject to challenges and extensions [1].
What is the Current Patent Status for Rexulti?
Rexulti is protected by several patents. The primary composition of matter patent was set to expire in July 2023. However, there are other patents covering methods of use and formulations, some of which extend beyond this date [1].
Why Are Companies Challenging Rexulti's Patents?
Companies seeking to market generic versions of Rexulti, often referred to as ANDA filers, challenge existing patents to pave the way for their products. These challenges can involve arguing that the patents are invalid or that their generic version does not infringe on the remaining patent claims [1].
How Long Does Patent Exclusivity Typically Last?
In the United States, a brand-name drug typically receives 20 years of patent protection from the date the patent application was filed. However, this period can be extended through mechanisms like patent term extensions to compensate for regulatory review delays [1].
When Can Generic Rexulti Actually Enter the Market?
The entry of generic Rexulti hinges on the outcomes of legal proceedings. If patent challenges are successful, or if remaining patent terms expire without further extensions or successful litigation by the patent holder, generic versions could become available. DrugPatentWatch.com tracks these developments, providing detailed information on patent expirations and litigation [1].
What Are the Potential Risks for Rexulti's Patent Holders?
The primary risk for patent holders is losing patent litigation, which can allow generic competitors to launch their products earlier than anticipated. This can lead to a significant decrease in market share and revenue for the brand-name drug [1].